Project description:We exposed Candida parapsilosis clinical isolate #12108 to YPD plate supplemented with 8µg/ml of tunicamycin. We randomly selected 18 adaptors. We did sequencing of these adaptors.
Project description:Candida parapsilosis wild type strain #12108 was exposed to 400ng/ml caspofungin. Randomly 30 adaptors were chosen. These adaptors as well as the parent were sequenced.
Project description:We used Candida albicans lab strain SC5314 to obtain tunicamycin adaptors. We did whole genome sequencing of the adaptors and the parent as well.
Project description:We exposed Candida parapsilosis clinical isolate #12108 to YPD plate supplemented with 40ng/ml of aureobasidin A. We randomly selected 18 adaptors. We did sequencing of these adaptors.
Project description:Candida auris clade III isolate B11221 was spread on YPD plate supplemented with 8 µg/ml tunicamycin. Randomly 18 adaptors were chosen for further analysis. We did sequencing of these 18 adaptors as well as the parent.
Project description:Candida parapsilosis clinical isolate #12584 was exposed to 3μg/ml and 4μg/ml amphotericin B. Randomly 30 adaptors (3 μg/ml) and 99 adaptors (4 μg/ml) were sequenced.
Project description:Candida parapsilosis chromosome 1 trisomy strain TJ74 was exposed to 400ng/ml caspofungin. Randomly 30 adaptors were chosen. These adaptors were sequenced.
Project description:Candida auris clade III isolate B12039 was spread on YPD plate supplemented with 8 µg/ml tunicamycin. Randomly 27 adaptors were chosen for further analysis. We did sequencing of these 27 adaptors as well as the parent.
Project description:Candida auris clade III isolate B12039 was spread on YPD plate supplemented with 4 µg/ml tunicamycin. Randomly 27 adaptors were chosen for further analysis. We did sequencing of these 27 adaptors as well as the parent.